Please login to the form below

Not currently logged in


This page shows the latest nab-paclitaxel news and features for those working in and with pharma, biotech and healthcare.

NICE turns down Roche’s Tecentriq for triple-negative breast cancer

NICE turns down Roche’s Tecentriq for triple-negative breast cancer

Tecentriq has been approved by the EMA for use in patients ineligible for surgery alongside Celgene’s Abraxane (nab-paclitaxel), and NICE estimates that around 600 of the 2, 000 women ... Baroness Delyth Morgan, chief executive at Breast Cancer Now

Latest news

More from news
Approximately 3 fully matching, plus 19 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...